Stocks · News reference

Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

Aug 14, 2026, 5:00 PMBenzinga Newsdesk

Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $22 to $21.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 13, 2026, 3:07 PMBenzinga Insights
Abeona Therapeutics Q2 2026 Earnings Call Transcript
Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data
Read original at benzinga
ABEO
BenzingaAug 13, 2026, 11:59 AMBenzinga Newsdesk
Abeona Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Read original at benzinga
ABEO
BenzingaAug 13, 2026, 11:31 AMBenzinga Newsdesk
Abeona Therapeutics Q2 EPS $(0.35) Misses $(0.23) Estimate, Sales $11.380M Miss $12.239M Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.23) by 52.17 percent. This is a 5.41 percent increase over losses of $(0.37) per share
Read original at benzinga
ABEO